Merck (MRK) Reports Positive One-Year Data from Phase 2b/3 Brunello Trial for Diabetic Macular Edema

gurufocus.com · 2026-10-11

On October 11, 2026, Merck & Co Inc (NYSE: MRK) announced initial one-year results from its pivotal Phase 2b/3 Brunello trial evaluating remigromig, a novel ant

TickrTrends take: Merck reported positive one-year data from its Phase 2b/3 Brunello trial for diabetic macular edema, a development that could support future revenue growth if the treatment advances to market approval. Given TickrTrends' current overvalued assessment of MRK, investors should monitor whether this clinical progress justifies the company's current valuation or if the market has already priced in such positive outcomes. In the competitive Healthcare sector, successful late-stage trial results often become reflected in stock price relatively quickly, so the timing and magnitude of any revenue contribution from this program would be key factors for reassessing the valuation verdict.

Read the full story at gurufocus.com →